Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Adjuvanted R21 at Two Different Doses and the Combination Malaria Vaccine Candidate Regimen of Adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP

Next Previous
Trial Profile

A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Adjuvanted R21 at Two Different Doses and the Combination Malaria Vaccine Candidate Regimen of Adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ME-TRAP malaria DNA vaccine Okairos (Primary) ; R 21 (Primary) ; Adjuvants; Antihistamines; Artemether/lumefantrine; Cyclizine; Paracetamol
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Jun 2018 Status changed from recruiting to completed.
    • 24 Apr 2018 Results (n=11; as of Feb 27) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 03 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top